{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:21:56Z","timestamp":1791973316936,"version":"4.3.4"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Solitary plasmacytoma (<jats:styled-content style=\"fixed-case\">SP<\/jats:styled-content>) and plasma cell leukemia (<jats:styled-content style=\"fixed-case\">PCL<\/jats:styled-content>) are uncommon (3\u20106%) types of plasma cell disease. The risk of progression to symptomatic multiple myeloma (<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>) is probably important for the outcome of <jats:styled-content style=\"fixed-case\">SP<\/jats:styled-content>. <jats:styled-content style=\"fixed-case\">PCL<\/jats:styled-content> is rare and has a dismal outcome. In this study, we report on incidence and survival in <jats:styled-content style=\"fixed-case\">PCL<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">SP<\/jats:styled-content>, and progression to <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">SP<\/jats:styled-content>, using the prospective observational Swedish Multiple Myeloma Register designed to document all newly diagnosed plasma cell diseases in Sweden since 2008. Both solitary bone plasmacytoma (<jats:styled-content style=\"fixed-case\">SBP<\/jats:styled-content>) (<jats:italic>n<\/jats:italic>=124) and extramedullary plasmacytoma (<jats:styled-content style=\"fixed-case\">EMP<\/jats:styled-content>) (<jats:italic>n<\/jats:italic>=67) have better overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) than <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> (<jats:italic>n<\/jats:italic>=3549). Progression to <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> was higher in <jats:styled-content style=\"fixed-case\">SBP<\/jats:styled-content> than in <jats:styled-content style=\"fixed-case\">EMP<\/jats:styled-content> (35% and 7% at 2\u00a0years, respectively), but this did not translate into better survival in <jats:styled-content style=\"fixed-case\">EMP<\/jats:styled-content>. In spite of treatment developments, the <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> of primary <jats:styled-content style=\"fixed-case\">PCL<\/jats:styled-content> is still dismal (median of 11\u00a0months, 0% at 5\u00a0years). Hence, there is a great need for diagnostic and treatment guidelines as well as prospective studies addressing the role for alternative treatment options, such as allogeneic stem cell transplantation and monoclonal antibodies in the treatment of <jats:styled-content style=\"fixed-case\">PCL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/ejh.12907","type":"journal-article","created":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T00:13:20Z","timestamp":1495584800000},"page":"216-222","source":"Crossref","is-referenced-by-count":63,"title":["Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population\u2010based data from the Swedish Myeloma Register"],"prefix":"10.1111","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4711-5094","authenticated-orcid":false,"given":"Hareth","family":"Nahi","sequence":"first","affiliation":[{"name":"Hematology Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Genell","sequence":"additional","affiliation":[{"name":"Regional Cancer Centre West  Gothenberg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"W\u00e5linder","sequence":"additional","affiliation":[{"name":"Hematology Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Uttervall","sequence":"additional","affiliation":[{"name":"Hematology Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Juliusson","sequence":"additional","affiliation":[{"name":"Hematology\/Lund University  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forsberg","family":"Karin","sequence":"additional","affiliation":[{"name":"Hematology Ume\u00e5 University Hospital  Ume\u00e5 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hansson","sequence":"additional","affiliation":[{"name":"Hematology\/Lund University  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Svensson","sequence":"additional","affiliation":[{"name":"Hematology Linkoping University Hospital  Linkoping Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Linder","sequence":"additional","affiliation":[{"name":"Hematology \u00d6rebro University Hospital  \u00d6rebro Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Carlson","sequence":"additional","affiliation":[{"name":"Uppsala University Hospital  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Bj\u00f6rkstrand","sequence":"additional","affiliation":[{"name":"Hematology Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurdur Y.","family":"Kristinsson","sequence":"additional","affiliation":[{"name":"Hematology Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf Henrik","family":"Mellqvist","sequence":"additional","affiliation":[{"name":"Hematology South Elvsborg Hospital  Boras Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie","family":"Blimark","sequence":"additional","affiliation":[{"name":"Hematology Sahlgrenska University Hospital  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingemar","family":"Turesson","sequence":"additional","affiliation":[{"name":"Hematology Skane University Hospital  Malm\u00f6 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2037"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07421.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13870"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23745"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.373"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.133.5.813"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90942-9"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24700"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb05114.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-016-0392-6"},{"key":"e_1_2_7_14_1","first-page":"1972","article-title":"Real world data in myeloma: Experiences from the Swedish population\u2010based registry on 2494 myeloma patients diagnosed 2008\u20132011","volume":"122","author":"Blimark C","year":"2013","journal-title":"Blood, Meeting Abstract"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22912"},{"key":"e_1_2_7_16_1","unstructured":"Subdistribution Analysis of Competing Risks. [Online] [Accessed]. Bob Gray (2014).cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2\u20107.https:\/\/CRAN.R-project.org\/package=cmprsk. Accessed June 17 2014."},{"key":"e_1_2_7_17_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2016"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(96)00334-3"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31819cca18"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.06.039"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.09.019"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04834.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-007-9011-5"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq646"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000210555"},{"key":"e_1_2_7_26_1","first-page":"36","article-title":"Treatment of multiple myeloma","volume":"84","author":"San Miguel JF","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.4"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12685"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.241"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1929"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-565051"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.6115"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1250263"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1244002"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12907","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T07:08:01Z","timestamp":1696316881000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,28]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/ejh.12907"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12907","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,28]]}}}